Alice M. Thomson

St Vincent's Hospital Melbourne
Fitzroy, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Natural history of lower urinary tract symptoms following transurethral resection of prostate: a prospective observational study.

Natural history of lower urinary tract symptoms following transurethral resection of prostate: a prospective observational study.

Journal: BJU international

Published: March 08, 2026

Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.

Effect of [68Ga]Ga-PSMA-11 PET-CT in the diagnosis of prostate cancer in men with equivocal or clinically high-risk non-suspicious findings on multiparametric MRI (PRIMARY2): a multicentre, non-inferiority, phase 3, randomised controlled trial.

Journal: The Lancet. Oncology

Published: February 13, 2026

Scribe smarter, not harder: how artificial intelligence scribes stack up against human clinicians.

Scribe smarter, not harder: how artificial intelligence scribes stack up against human clinicians.

Journal: BJU international

Published: October 10, 2025

The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-analysis.

The Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Assessment of Local Recurrence and Distant Metastases in Patients with Biochemical Recurrence of Prostate Cancer After Definitive Treatment: A Systematic Review and Meta-analysis.

Journal: European urology

Published: January 14, 2025

Time to castrate the cost? the rising expense of chemical castration for the management of prostate cancer.

Time to castrate the cost? the rising expense of chemical castration for the management of prostate cancer.

Journal: Prostate international

Published: December 08, 2024

A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment.

A Comprehensive Systematic Review and Meta-analysis of the Role of Prostate-specific Membrane Antigen Positron Emission Tomography for Prostate Cancer Diagnosis and Primary Staging before Definitive Treatment.

Journal: European urology

Published: November 11, 2024

Re: Radical Prostatectomy Without Prior Biopsy in Selected Patients Evaluated by 18F-Labeled Prostate-specific Membrane Antigen-Ligand Positron Emission Tomography/Computed Tomography and Multiparameter Magnetic Resonance Imaging: A Single-center, Prospective, Single-arm Trial.

Re: Radical Prostatectomy Without Prior Biopsy in Selected Patients Evaluated by 18F-Labeled Prostate-specific Membrane Antigen-Ligand Positron Emission Tomography/Computed Tomography and Multiparameter Magnetic Resonance Imaging: A Single-center, Prospective, Single-arm Trial.

Journal: European urology

Published: July 11, 2024

Re: [177Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ENZA-p): An Open-label, Multicentre, Randomised, Phase 2 Trial.

Re: [177Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ENZA-p): An Open-label, Multicentre, Randomised, Phase 2 Trial.

Journal: European urology

Published: May 28, 2024

Re: Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer.

Re: Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer.

Journal: European urology

Published: May 25, 2024

Re: First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma.

Re: First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma.

Journal: European urology

Published: March 11, 2024

A critical evaluation of Optilume® BPH as a novel minimally invasive surgical treatment for the management of lower urinary tract symptoms in men.

A critical evaluation of Optilume® BPH as a novel minimally invasive surgical treatment for the management of lower urinary tract symptoms in men.

Journal: Translational andrology and urology

Published: November 13, 2023

Patient-centred pathology reporting improves patient experience and understanding of disease in prostate cancer care.

Patient-centred pathology reporting improves patient experience and understanding of disease in prostate cancer care.

Journal: BJUI compass

Published: September 25, 2023

Showing 1-12 of 19

Last Updated: 09/26/2026